In the run up to the 2025 annual ASCO meeting, IMUNON (Nasdaq: IMNN) is moving into a Phase III trial with its lead candidate IMNN-001.
1 month ago

Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.
53 months ago

Celsion rebrands to Imunon to reflect immunotherapy, COVID-19 vaccine ambitions ... As it continues to push its DNA-based interleukin-12 (IL-12)...
33 months ago

Imunon, Inc. (NASDAQ:IMNN), a pharmaceutical company based in Lawrenceville, NJ, with a market capitalization of $6.17 million, has formally withdrawn its...
1 month ago

Celsion's PLACCINE platform is the company's proprietary plasmid and DNA delivery technology. A single plasmid DNA characterizes the platform...
46 months ago

The OVATION 2 Study is an open-label, 1-to-1 randomized trial, 80% powered to show the equivalent of a 33% improvement in progression-free survival (PFS).
52 months ago

GEN-1 is a nanoparticle containing the DNA sequence for the pro-inflammatory protein interleukin-12 (IL-12). When delivered to the tumor, GEN-1...
82 months ago

Celsion Corp., a biopharmaceutical company developing mid-to-later stage therapies for cancer, recently acquired EGEN, Inc., a drug developer with a proven...
131 months ago

This marks a major initiative for Imunon CEO Dr. Corinne Le Goff, who joined the company after serving as chief commercial officer at...
33 months ago

The team has applied for a license under the name Celsion Bank with the Financial Markets Authority (FMA) in Liechtenstein.
13 months ago